Chemicals & Biochemicals

Hyperforin . DCHA

NEW
Hyperforin . DCHA

Article No

AG-CN2-0008-C500

Size

500 µg

Source / Host

plant

Shipping Information

Ambient

Product insert

Specifications

CAS No 238074-03-8
MW 535.8 . 182.3
Additional Information The DCHA salt stabilizes hyperforin which normally has only a short shelf life.
Article No AG-CN2-0008-C500
Country Availability DK, EE, FI, IS, LT, LV, NO, SE
Description Hyperforin . DCHA
Supplier Adipogen Life Sciences
Format Powder
Notes Key constituent of St. John's wort. Shows properties of potential pharmacological interest, including antibacterial, anti-malarial, anti-inflammatory, anti-cancer and anti-angiogenic effects. Anti-depressant and anxiolytic compound. Specific activator of TRPC6 channels. Inhibits the re-uptake of neurotransmitters in synapses (serotonin, norepinephrine, dopamine, GABA, glutamate). Activator of the pregnane X receptor (PXR). Regulates expression of the cytochrome P450 CYP3A4 and CYP2C9 and hepatic drugs metabolism. Potential anti-Alzheimer compound. Potent SIRT1 (sirtuin 1) and SIRT2 (sirtuin 2) inhibitor.
Molecular Formula C35H51O4 . C12H24N
Alias Names (1R,5R,6R,7S)-2-Hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-enyl)-6-(4-methylpent-3-enyl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-2-ene-4,9-dione . DCHA
Product Type Chemicals & Biochemicals
Protocol The DCHA salt stabilizes hyperforin which normally has only a short shelf life.
Purity >97% (HPLC)
References Antibacterial activity of hyperforin from St John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria: C.M. Schempp, et al.; Lancet 353, 2129 (1999) | St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor: L.B. Moore, et al.; PNAS 97, 7500 (2000) | Hyperforin-antidepressant activity by a novel mechanism of action: W.E. Müller, et al.; Pharmacopsychiatry 34 (Suppl 1), S98 (2001) | Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology: P.J. Nathan; J. Psychopharmacol. 15, 47 (2001) (Review) | Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis: C.M. Schempp, et al.; Oncogene 21, 1242 (2002) | Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John's wort: M.L. Buchholzer, et al.; J. Pharmacol. Exp. Ther. 301, 714 (2002) | Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase: D. Albert, et al.; Biochem. Pharmacol. 64, 1767 (2002) | Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures: B.J. Komoroski; Drug Metab. Dispos. 32, 512 (2004) | NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's Wort: V. Kumar, et al.; J. Pharmacol. Sci. 102, 47 (2006) | Hyperforin, a new lead compound against the progression of cancer and leukemia? C. Quiney, et al.; Leukemia 20, 1519 (2006) | Hyperforin-a key constituent of St. John's wort specifically activates TRPC6 channels: K. Leuner, et al.; FASEB J. 21, 4101 (2007) | Phloroglucinol derivatives guttiferone G, aristoforin, and hyperforin: inhibitors of human sirtuins SIRT1 and SIRT2: C. Gey, et al.; Angew. Chem. Int. Ed. Engl. 46, 5219 (2007) | In vitro antimalarial activity of hyperforin, a prenylated acylphloroglucinol. A structure-activity study: L. Verotta, et al.; Bioorg. Med. Chem. Lett. 17, 1544 (2007) | Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo: C. Feisst, et al.; Cell. Mol. Life Sci. 66, 2759 (2009) | Neurobiological effects of Hyperforin and its potential in Alzheimer's disease therapy: T.N. Griffith, et al.; Curr. Med. Chem. 17, 391 (2010)
Research Area Metabolism
Shipping Information Ambient
Size 500 µg
Solubility Soluble in 100% ethanol, methanol or DMSO.
Source / Host plant
Stability Stable for at least 2 years after receipt when stored at -20°C.
Storage -20°C
Technical Specifications Chemical. CAS: 238074-03-8. Formula: C35H51O4 . C12H24N. MW: 535.8 . 182.3. Isolated from St. John's wort (Hypericum perforatum). Key constituent of St. John's wort. Shows properties of potential pharmacological interest, including antibacterial, anti-malarial, anti-inflammatory, anti-cancer and anti-angiogenic effects. Anti-depressant and anxiolytic compound. Specific activator of TRPC6 channels. Inhibits the re-uptake of neurotransmitters in synapses (serotonin, norepinephrine, dopamine, GABA, glutamate). Activator of the pregnane X receptor (PXR). Regulates expression of the cytochrome P450 CYP3A4 and CYP2C9 and hepatic drugs metabolism. Potential anti-Alzheimer compound. Potent SIRT1 (sirtuin 1) and SIRT2 (sirtuin 2) inhibitor.
Product Page Updated 2019-07-12T09:17:06.689Z

Shipping info

The delivery time for this item is approximately 5-8 business days. 
If other deviations occur, this will be noted on the order confirmation or communicated via email.
Please note, we do reserve the right to select the best packaging and shipping method in order to insure the stability of the product and allow efficient order tracking.